Editors’ Picks, April 2024: Targeting Metabolism, KRAS, and More
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
April picks include metabolic interventions for acute myeloid leukemia, new inhibitors of KRAS signaling, and more.
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
The AACR Annual Meeting 2024 Opening Plenary showed how researchers are inspiring science, fueling progress, and revolutionizing care.
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
Researchers are exploring new options for kidney cancer treatments.
Researchers are finding early clinical success in developing more targeted treatments for bile duct cancer, also called cholangiocarcinoma.
In the final quarter of 2023, the FDA issued 17 approvals specifically for the treatment of tumors.
As the deep reds and yellows of fall leaves give way to twinkling holiday lights, we welcome the new...
With a five-year survival rate of only 12.5%, any progress toward new therapeutic approaches for pancreatic cancer is welcomed...
As you prepare for trick-or-treating, check out the articles selected by the editors of the 10 AACR journals for...